alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413. 6 Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C et al.
To the Editor: Tyrosine kinase inhibitors (TKIs) efficiently induce rapid hematologic and cytogenetic responses in most chronic myeloid leukemia (CML) patients. TKI therapy has been considered to be life long, as rapid leukemia relapses are often observed in patients who discontinue treatment. The cause for relapse is unknown, but has been related to TKI resistance of the leukemic stem cells (LSCs) and/or immune tolerance of CML cells. Accordingly, in vitro experiments have suggested that TKIs have an antiproliferative, but not a proapoptotic or cytotoxic effect on the most primitive CML stem cells (Ph þ CD34 þ CD38 neg cells). 1, 2 Second generation TKI dasatinib has been shown to have a more profound effect on the stem cell compartment when compared to imatinib or nilotinib, but the drug was still unable to kill the most primitive CD34 þ CD38 neg LSCs in vitro. 2 The causes for stem cell resistance are unclear. In a recent study, primitive leukemic cells had higher BCR-ABL1 and CRKL kinase activity levels when compared with more mature cells. In addition, mRNA expression level of the imatinib uptake pump OCT-1 was lower and the drug efflux transporter protein ABCB1 (MDR) and ABCG2 levels were higher. 3 The stem cell persistence has also been implied in previous publications showing small numbers of Ph þ CD34 þ progenitor cells in bone marrow (BM) of CML patients even after years on TKI therapy. 4, 5 However, recent observations suggest that in a substantial proportion of CML patients who have reached complete molecular remission during TKI treatment, therapy can be discontinued without imminent relapse of the disease. 6 The molecular or cellular mechanisms for 'cure' are unknown, but either the therapy has eradicated the LSCs or they are under a transcriptional control by the immune system preventing stem cell proliferation and expansion. Thus far there are no reports describing the prevalence of the most primitive CML stem cells (CD34 þ CD38 neg ) in patients during TKI therapy. The aim of this project was to analyze the Philadelphia chromosome-positive (Ph þ ) LSCs in CML patients who have achieved a good response to TKI therapy.
A total of 25 chronic phase CML patients were included in the study; 17 patients were treated with imatinib (3 of them had discontinued treatment as per a study protocol), 5 with dasatinib, and 3 with bosutinib. The median time of TKI treatment was 21 months (range 3-72 months, Table 1 Figure 1a) . The lowest 5% of cells were regarded CD38 negative. Cytospin slides were prepared from sorted cells (15 000-45 000 cells/slide).
From a proportion of samples additional staining was carried out with CD19, CD117, CD133, and CD13/33 antibodies to characterize the phenotype of different fractions.
All antibodies were purchased from BD Biosciences (San Jose, CA, USA). The FACS sorting and analysis were performed with FACSAria flowcytometer (BD).
Interphase FISH analysis was carried out on cytospin slides using locus-specific dual color, dual fusion BCR-ABL1 probe mixture (Vysis, Downers Crove, IL, USA) (Figures 1a and b) . Hybridizations were performed according to the manufacturer's instructions. Up to 1000 cells were aimed to be analyzed from every slide. The false positivity rate of the method is considered to be close to 0%. A highly sensitive metaphase fluorescence in situ hybridization (FISH) from a median of 1000 BM cells (instead of conventional G-banding of 20 metaphases) was used to define complete cytogenetic remission (CCyR). Molecular genetic analyses of BCR-ABL1 transcripts were carried out with standardized real-time quantitative PCR and the results were expressed on the international scale.
The median volume of collected BM aspirates was 30 ml (range 5-55 ml) with a median yield of 280 Â 10 6 mononuclear cells per sample. The median amount of CD34 þ CD38 neg cells obtained was 32 000 (range 1000-91 000) denoting that 1-3 cytospin slides of the most CD38-negative cell fraction were available for FISH analysis. The median number of interphase nuclei analyzed was 1005 with no difference in the different stem cells fractions (median number of 1004, 1002, and 1010 cells analyzed in CD34 þ CD38 high , CD34 þ CD38 med , and CD34 þ CD38 neg cell fractions, respectively). Although the analysis required large volume BM aspirates, it was feasible with minimal additional patient discomfort and representative samples were obtained from each patient with good quality FISH results (Figures 1a and b) .
Of the 25 patients studied, 18 were in CCyR when assessed by whole BM metaphase FISH (1000 cells evaluated). Surprisingly, from only 2/18 (11%) patients in CCyR could residual leukemic cells be detected in any of the sorted CD34 þ cell fractions and in very small amounts (less than 1% Ph þ cells) ( fractions, whereas in the other two patients no Ph þ cells could be found, even when up to 1000 cells were analyzed in each case. Four out of seven non-CCyR patients had significant residual disease on sample analysis (5-20% of Ph þ cells in nonfractionated BM sample). All of them had previously been in CCyR, but three had lost CCyR during discontinuation of imatinib treatment (per a study protocol) and one patient developed secondary resistance because of emergence of an imatinib resistant BCR-ABL1 kinase domain mutation L248V (patient 21, Table 1 Table 1 ). This suggests that in the patients relapsing after the cessation of TKI therapy, the transcriptional control of the rare existing LSCs is nonexistent and on drug discontinuation the LSCs proliferate and differentiate rapidly without any control from the immune system producing abundant amount of Ph þ cells in the more mature fractions. In healthy normal individuals, the majority of BM CD34 þ CD38 þ cells are CD19-expressing progenitor B-cells, whereas the CD34 þ CD38 neg cells do not express CD19. In contrast, in untreated CML patients, only a minority of CD34 þ CD38 þ cells express the CD19 antigen (results not shown), reflecting dominance of granulopoiesis typical of the disease. However, earlier publications have shown that in CML, the progenitor B-cells also belong to the malignant Ph þ clone + cells were divided into three different fractions based on the CD38 expression: high, medium, negative (o5%). BM, bone marrow; CML, chronic myeloid leukemia; IFN, interferon-a; NA, not analyzed; TKI, tyrosine kinase inhibitor.
Letters to the Editor and only mature T cells are Ph negative. 7 In the patient cohort from which stem cell sorting was carried out (CML patients in CCyR), CD34 þ cells expressing the highest CD38 antigen level (Figures 1a and c) were predominantly CD19 positive, thus resembling the situation seen in normal healthy BM. The CD34 þ cells with low CD38 antigen level expressed CD117 (C-KIT) and CD133 (Figures 1a and c) confirming their more primitive nature.
Our data of chronic phase CML patients indicated that TKI therapy eradicates most Ph þ CD34 þ progenitor cells when analyzed from standard clinical BM aspirates. Surprisingly, residual LSCs could not be detected even in the most primitive CD34 þ CD38 neg cell fraction in vivo. On the basis of the estimates of stem cell frequency, our high-resolution FISH method is adequately sensitive and comparable to real-time quantitative PCR. Increasing the sensitivity of the assay (FISH or PCR) would require aspiration of impractical amounts of BM. Furthermore, FISH analysis gives more precise estimate of the actual number of residual Ph þ LSCs when compared with PCR as higher BCR-ABL1 transcript level in CD34 þ CD38 neg cells 3 and possible amplification of RNA because of small cell number can affect the results of PCR assay.
These results differ from the in vitro studies, in which CD34 þ CD38 neg cells have been shown to be resistant to TKIs.
1,2 However, recent observations imply that TKI therapy can be discontinued in a proportion of patients in complete molecular remission. 6 Our data suggest mechanistic explanation to this observation and support the theory that in vivo, TKIs eradicate majority of LSCs and therefore for successful imatinib discontinuation the restoration of anti-CML immune control is likely a more determining factor than the level of residual LSCs.
The difference between in vivo and in vitro settings could partly be becuse of non-physiological conditions (growth factor sensitivity, other cytokines) in cell culture assays. Some residual Ph þ cells can exist, but our observations indicate that they are very rare and not enriched in the most primitive CD34 þ CD38 neg fraction. Further, recent mouse studies have shown that both normal and LSCs reside in the hypoxic endosteal niche separate from the medullary central BM. 8 The fact that matrix-bound subendosteal cells are rarely, if ever, aspirated with conventional BM puncture methods, may partly explain the paucity of LSCs in our patient samples.
By definition, cure of leukemia requires eradication or transcriptional control of LSCs. This can be achieved by high- dose chemotherapy in a proportion of patients with acute leukemia, but with significant therapy-related morbidity and mortality. The successful therapy outcome can also be affected by the number of LSCs at diagnosis and based on our unpublished data, the proportion of Ph þ CD34 cells vary significantly (median 92%, range 52-99%, n ¼ 9) between different CML patients at diagnosis. Recently, several agents, such as a farnesyltransferase inhibitor (BMS 214662) 9 or parthenolide, 10 have been shown to selectively target and kill CML and acute myeloid leukemia LSCs in vitro, respectively. Future clinical studies with these novel stem cell targeting drugs will necessitate accurate assessment of LSC burden in patients. LSC analysis may also have prognostic significance in evaluating the response to cytotoxic therapy in acute leukemia. However, novel technical innovations and techniques for assessing the BM microenvironment as a whole, such as tracking LSCs in vivo with high-resolution positron emission tomography, would be most useful to make response evaluation more comprehensive.
In conclusion, in chronic phase CML, successful TKI therapy eradicates most Ph þ CD34 þ CD38 neg cells from the central BM. Prospective studies analyzing the kinetics of LSC disappearance after the start of TKI therapy will shed more light on the depth of the therapy response at the stem cell level. On the basis of our data, significant reduction in the number of LSCs by TKI therapy is feasible and when accompanied with restoration of anti-CML immune control, can explain the prolonged remissions observed in a proportion of patients discontinuing TKI therapy.
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